EGETIS THERAPEUTICS (Germany) Today
| P0F Stock | EUR 0.33 0.01 3.13% |
PerformanceVery Weak
| Odds Of DistressQuite High
|
EGETIS THERAPEUTICS is trading at 0.33 as of the 22nd of March 2025. This is a 3.13 percent increase since the beginning of the trading day. The stock's lowest day price was 0.32. EGETIS THERAPEUTICS has more than 65 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Egetis Therapeutics AB , a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rareniche diseases with unmet medical needs in the orphan drug segment. Egetis Therapeutics AB was founded in 2006 and is based in Stockholm, Sweden. The company has 214.59 M outstanding shares. More on EGETIS THERAPEUTICS AB
Moving together with EGETIS Stock
Moving against EGETIS Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
EGETIS Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. EGETIS THERAPEUTICS's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding EGETIS THERAPEUTICS or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chief Executive Officer | Nicklas Westerholm |
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
EGETIS THERAPEUTICS AB (P0F) is traded on Frankfurt Exchange in Germany and employs 17 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 110.51 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate EGETIS THERAPEUTICS's market, we take the total number of its shares issued and multiply it by EGETIS THERAPEUTICS's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. EGETIS THERAPEUTICS classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 214.59 M outstanding shares.
Check EGETIS THERAPEUTICS Probability Of Bankruptcy
Ownership AllocationEGETIS THERAPEUTICS holds a total of 214.59 Million outstanding shares. EGETIS THERAPEUTICS AB shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 60.64 percent of EGETIS THERAPEUTICS outstanding shares that are owned by insiders denotes they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check EGETIS Ownership Details
EGETIS THERAPEUTICS Risk Profiles
Although EGETIS THERAPEUTICS's alpha and beta are two of the key measurements used to evaluate EGETIS THERAPEUTICS's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.61 | |||
| Standard Deviation | 3.51 | |||
| Variance | 12.34 | |||
| Risk Adjusted Performance | (0.18) |
EGETIS Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in EGETIS THERAPEUTICS without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Premium Stories Now
Premium StoriesFollow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
| All Next | Launch Module |
EGETIS THERAPEUTICS Corporate Management
Elected by the shareholders, the EGETIS THERAPEUTICS's board of directors comprises two types of representatives: EGETIS THERAPEUTICS inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EGETIS. The board's role is to monitor EGETIS THERAPEUTICS's management team and ensure that shareholders' interests are well served. EGETIS THERAPEUTICS's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EGETIS THERAPEUTICS's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Walberg | Executive Director, Interim Chief Medical Officer | Profile | |
| Sten Nilsson | Director | Profile | |
| Marie Bengtson | Clinical Project Director | Profile | |
| Henrik Krook | Vice President - Commercial Operations | Profile | |
| Gunilla Osswald | Director | Profile | |
| Malin Nittve | Project Manager, Director of Regulatory Affairs | Profile | |
| Marie Tragardh | Director | Profile |
Other Information on Investing in EGETIS Stock
EGETIS THERAPEUTICS financial ratios help investors to determine whether EGETIS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in EGETIS with respect to the benefits of owning EGETIS THERAPEUTICS security.